IRADIMED CORP (IRMD) Stock Price & Overview

NASDAQ:IRMDUS46266A1097

Current stock price

99.5 USD
-0.35 (-0.35%)
At close:
99.5 USD
0 (0%)
After Hours:

The current stock price of IRMD is 99.5 USD. Today IRMD is down by -0.35%. In the past month the price decreased by -3.92%. In the past year, price increased by 90.14%.

IRMD Key Statistics

52-Week Range47.4775 - 107.9
Current IRMD stock price positioned within its 52-week range.
1-Month Range95.8715 - 107
Current IRMD stock price positioned within its 1-month range.
Market Cap
1.272B
P/E
51.82
Fwd P/E
46.90
EPS (TTM)
1.92
Dividend Yield
0.71%

IRMD Stock Performance

Today
-0.35%
1 Week
-0.19%
1 Month
-3.92%
3 Months
+2.38%
Longer-term
6 Months +41.09%
1 Year +90.14%
2 Years +126.19%
3 Years +152.86%
5 Years +286.11%
10 Years +419.31%

IRMD Stock Chart

IRADIMED CORP / IRMD Daily stock chart

IRMD Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to IRMD. When comparing the yearly performance of all stocks, IRMD is one of the better performing stocks in the market, outperforming 92.84% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

IRMD Fundamental Analysis

ChartMill assigns a fundamental rating of 8 / 10 to IRMD. Both the health and profitability get an excellent rating, making IRMD a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IRMD Earnings

On February 10, 2026 IRMD reported an EPS of 0.54 and a revenue of 22.69M. The company beat EPS expectations (10.29% surprise) and beat revenue expectations (3% surprise).

Next Earnings DateMay 4, 2026
Last Earnings DateFeb 10, 2026
PeriodQ4 / 2025
EPS Reported$0.54
Revenue Reported22.692M
EPS Surprise 10.29%
Revenue Surprise 3.00%

IRMD Forecast & Estimates

8 analysts have analysed IRMD and the average price target is 122.4 USD. This implies a price increase of 23.02% is expected in the next year compared to the current price of 99.5.

For the next year, analysts expect an EPS growth of 10.5% and a revenue growth 11.27% for IRMD


Analysts
Analysts82.5
Price Target122.4 (23.02%)
EPS Next Y10.5%
Revenue Next Year11.27%

IRMD Groups

Sector & Classification

IRMD Financial Highlights

Over the last trailing twelve months IRMD reported a non-GAAP Earnings per Share(EPS) of 1.92. The EPS increased by 16.36% compared to the year before.


Income Statements
Revenue(TTM)83.81M
Net Income(TTM)21.18M
Industry RankSector Rank
PM (TTM) 26.31%
ROA 18.47%
ROE 21.54%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%22.73%
Sales Q2Q%17.03%
EPS 1Y (TTM)16.36%
Revenue 1Y (TTM)14.43%

IRMD Ownership

Ownership
Inst Owners60.49%
Shares12.78M
Float8.10M
Ins Owners36.78%
Short Float %6.49%
Short Ratio7.07

About IRMD

Company Profile

IRMD logo image IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. The company is headquartered in Orlando, Florida and currently employs 166 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.

Company Info

IPO: 2014-07-16

IRADIMED CORP

12705 Ingenuity Drive

Orlando FLORIDA 32708 US

CEO: Roger Susi

Employees: 166

IRMD Company Website

IRMD Investor Relations

Phone: 18009279800

IRADIMED CORP / IRMD FAQ

Can you describe the business of IRADIMED CORP?

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. The company is headquartered in Orlando, Florida and currently employs 166 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.


Can you provide the latest stock price for IRADIMED CORP?

The current stock price of IRMD is 99.5 USD. The price decreased by -0.35% in the last trading session.


What is the dividend status of IRADIMED CORP?

IRADIMED CORP (IRMD) has a dividend yield of 0.71%. The yearly dividend amount is currently 1.18.


What is the ChartMill rating of IRADIMED CORP stock?

IRMD has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 8 out of 10.


On which exchange is IRMD stock listed?

IRMD stock is listed on the Nasdaq exchange.


What is the Price/Earnings (PE) ratio of IRADIMED CORP (IRMD)?

The PE ratio for IRADIMED CORP (IRMD) is 51.82. This is based on the reported non-GAAP earnings per share of 1.92 and the current share price of 99.5 USD.


Is IRADIMED CORP (IRMD) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IRMD.